For the year ending 2025-12-31, SBRA had $11,410K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 155,510 |
| Depreciation and amortization | 186,996 |
| Non-cash rental and related revenues | -1,020 |
| Non-cash interest income | -7 |
| Non-cash interest expense | 7,970 |
| Stock-based compensation expense | 11,360 |
| Loss on extinguishment of debt | -1,154 |
| (recovery of) provision for loan losses | -1,047 |
| Net loss (gain) on sales of real estate | -3,519 |
| Impairment of real estate | 7,322 |
| (income) loss from unconsolidated joint ventures | 3,928 |
| Distributions of earnings from unconsolidated joint ventures | 7,813 |
| Other non-cash items | -17,190 |
| Accounts receivable, prepaid expenses and other assets, net | 11,449 |
| Accounts payable and accrued liabilities | 1,596 |
| Net cash provided by operating activities | 348,613 |
| Acquisition of real estate and lease intangibles | 452,933 |
| Origination and fundings of loans receivable | 6,910 |
| Origination and fundings of preferred equity investments | 9 |
| Additions to real estate | 41,521 |
| Repayments of loans receivable | 20,671 |
| Repayments of preferred equity investments | -2,533 |
| Investment in unconsolidated joint ventures | 1,241 |
| Net proceeds from the sales of real estate | 88,637 |
| Net proceeds from sales-type lease | 0 |
| Proceeds from net investment hedges | 4,462 |
| Insurance proceeds | 1,589 |
| Distributions in excess of earnings from unconsolidated joint ventures | 6,762 |
| Net cash (used in) provided by investing activities | -377,960 |
| Net borrowings from revolving credit facility | 109,805 |
| Principal payments on senior unsecured notes | 500,000 |
| Proceeds from term loans | 500,000 |
| Principal payments on secured debt | 2,089 |
| Payments of deferred financing costs | 4,405 |
| Payments related to extinguishment of debt | 2,884 |
| Contributions from noncontrolling interests | 2,046 |
| Payment of contingent consideration | 0 |
| Issuance of common stock, net | 227,781 |
| Dividends paid on common stock | 289,497 |
| Net cash provided by (used in) financing activities | 40,757 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 11,410 |
| Effect of exchange rate changes on cash | 391 |
| Cash and cash equivalents at beginning of period | 66,339 |
| Cash and cash equivalents at end of period | 78,140 |
Sabra Health Care REIT, Inc. (SBRA)
Sabra Health Care REIT, Inc. (SBRA)